Published: Sep, 2018
The global liquid biopsy market is prognosticated to witness healthy growth in the coming years, according to report published by Transparency Market Research (TMR). Currently, the liquid biopsy market is in its nascent stage and it is expanding at an exponential rate. There are a number of new players entering the market, fostering the adoption of collaborations among the market vendors. A strong support from research institutes is expected, on account of the liquid biopsy market is bound to witness rampant diversification and growth in the coming years.
Several biotechnological companies have started their trials in China as clinical trial regulations are comparatively lenient. This is encouraging companies to shift their base from America and Europe, where costlier trials are required for approval and reimbursement. Thus, vendors are looking at expanding at their facilities to emerging nations, or regions with lower cost of approvals.
The prominent players in the global liquid biopsy market are Bio-Rad Laboratories, MDxHealth, Genomic Health, Inc. Thermo Fisher Scientific Inc., Biocept, Inc., and Myriad Genetics, Inc.
According to TMR’s projections, the global liquid biopsy market is anticipated to rise at a CAGR of 10.1% over the forecast period of 2018 to 2026. The estimated market worth stood at US$ 3,883.2 Mn in 2017.
Request a Sample of Liquid Biopsy Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=22994
Rising Prevalence of Cancer to Propel Market
As a growing assemblage of proof shows intertumoral and intratumoral heterogeneity and clonal advancement, both during carcinogenesis and furthermore all through treatment bringing about gained drug obstruction, the utility of blood?based tests or liquid biopsies is ending up progressively perceived in clinical practice and preliminary design. Liquid biopsies give a less obtrusive way to deal with the present highest quality level of analyzing tumors by tissue biopsies, which are every now and again unfeasible, and can't be executed as regularly.
Three key utilizations of liquid biopsy can be treatment choice instrument for metastatic bosom cancers, treatment determination for other metastatic cancers, and atomic health analysis. With the rising frequency of metastatic cancer over the globe, the treatment choice device for metastatic breast cancer segment is expected to hold an extensive share in the market in the coming years. The benefits of liquid biopsy over solid tumor biopsy, ascend in mindfulness about minimally invasive procedures, great government activities, and nearness of enormous cancer populace base are central point that drive the global liquid biopsy market.
Increased Adoption of Biomarkers to Offer Lucrative Opportunities
The extracellular vesicles segment is the swiftest developing one in the circulating biomarkers in the market for liquid biopsy. This is because of the developing interest for study of biofluids, for example, the blood and urine of tumor patients as a methods for disease analysis and remedial observing. There are right now 8-10 types of liquid biopsy tests in view of CTCs and ctDNA that are being utilized. Besides, more than 30 tests in view of each of the three of these biomarkers are in clinical advancement by some key market members, for instance, Qiagen, Trovagene, and Biocept. Commercialization of these tests in the offing is evaluated to profit the growth of the global liquid biopsy market in the coming years. Liquid tumor cells tests are relevant in portrayal of tumor cells through biochemical marker analysis, and is expected to offer rich growth opportunity to market vendors.
This review is based on TMR’s report titled, “Liquid Biopsy Market (Application - Oncology, NIPT, Transplant Diagnostics; Circulating Biomarker - Circulating Tumor Cells (CTC), Free Nucleic Acid, Extracellular Vesicles; End use - Hospitals, Reference Laboratories, Academic and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.”Top of Form
The market is segmented along the following lines:
Global Liquid Biopsy Market, by Application
- Transplant Diagnostics
Global Liquid Biopsy Market, by Circulating Biomarker
- Circulating Tumor Cells (CTC)
- Free Nucleic Acid
- Extracellular vesicles/Exosomes
Global Liquid Biopsy Market, by End-user
- Reference Laboratories
- Academic and Research Institutes
Global Liquid Biopsy Market, by Region
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR Syndicated Research report covers a different sector — such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.
90 Sate Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453